Cellosaurus logo
expasy logo

Cellosaurus HEC-1 (CVCL_1274)

[Text version]
Cell line name HEC-1
Synonyms HEC1; Human Endometrial Cancer-1; HEC-B-296
Accession CVCL_1274
Resource Identification Initiative To cite this cell line use: HEC-1 (RRID:CVCL_1274)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Population: Japanese.
Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
Sequence variations
  • Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (Cosmic-CLP=907051; DepMap=ACH-001517).
  • Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (DepMap=ACH-001517).
  • Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; ClinVar=VCV001736936; Zygosity=Heterozygous; Note=Splice donor mutation (Cosmic-CLP=907051; DepMap=ACH-001517).
  • Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (DepMap=ACH-001517).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP=907051; DepMap=ACH-001517).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American0
East Asian, North89.14
East Asian, South10.41
South Asian0.45
European, North0
European, South0
Disease Endometrial adenocarcinoma (NCIt: C7359)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_0293 (HEC-1-A)CVCL_S835 (HEC-1C)CVCL_S836 (HEC-1D)
Sex of cell Female
Age at sampling 71Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP=907051; DepMap=ACH-001517; JCRB=JCRB0042

Markers:
AmelogeninX
CSF1PO10,12
D3S135815
D5S81811,13
D7S82011
D8S117913,14
D13S31711 (JCRB=JCRB0042)
11,16 (Cosmic-CLP=907051; DepMap=ACH-001517)
D16S53911,12
D18S5116,20,21
D21S1130,31
FGA21,22
Penta D9,13
Penta E11
TH016,7
TPOX11
vWA18

Run an STR similarity search on this cell line
Web pages https://tcpaportal.org/mclp/
Publications

PubMed=4673779; DOI=10.1016/0002-9378(72)90861-7
Kuramoto H., Tamura S., Notake Y.
Establishment of a cell line of human endometrial adenocarcinoma in vitro.
Am. J. Obstet. Gynecol. 114:1012-1019(1972)

PubMed=4678779
Kuramoto H.
Studies of the growth and cytogenetic properties of human endometrial adenocarcinoma in culture and its development into an established line.
Acta Obstet. Gynaecol. Jpn. 19:47-58(1972)

PubMed=7448794
Gal D., MacDonald P.C., Porter J.C., Smith J.W., Simpson E.R.
Effect of cell density and confluency on cholesterol metabolism in cancer cells in monolayer culture.
Cancer Res. 41:473-477(1981)

PubMed=2064198; DOI=10.1111/j.1749-6632.1991.tb37884.x
Kuramoto H., Nishida M., Morisawa T., Hamano M., Hata H., Kato Y., Ohno E., Iida T.
Establishment and characterization of human endometrial cancer cell lines.
Ann. N. Y. Acad. Sci. 622:402-421(1991)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=12227503; DOI=10.1111/j.1749-0774.2002.tb00103.x
Kuramoto H., Hamano M., Imai M.
HEC-1 cells.
Hum. Cell 15:81-95(2002)

DOI=10.1007/978-4-431-53981-0_1
Kuramoto H., Hamano M., Imai M., Fujisawa T., Kamata Y., Arai T., Kawaguchi M.
HEC-1 cells: establishment of an in vitro experimental system in endometrial carcinoma.
(In book chapter) Cell and molecular biology of endometrial carcinoma; Kuramoto H., Nishida M. (eds.); pp.3-34; Springer; Tokyo; Japan (2003)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) JCRB; JCRB0042
Cell line databases/resources CLO; CLO_0037162
cancercelllines; CVCL_1274
Cell_Model_Passport; SIDM00596
Cosmic-CLP; 907051
DepMap; ACH-001517
LINCS_HMS; 50014
LINCS_LDP; LCL-1496
Biological sample resources BioSample; SAMN03472810
CRISP screens repositories BioGRID_ORCS_Cell_line; 867
Chemistry resources ChEMBL-Cells; CHEMBL3308740
ChEMBL-Targets; CHEMBL1075462
GDSC; 907051
PharmacoDB; HEC1_523_2019
PubChem_Cell_line; CVCL_1274
Encyclopedic resources Wikidata; Q54882245
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM827285
GEO; GSM1669873
Polymorphism and mutation databases Cosmic; 907051
IARC_TP53; 21367
Progenetix; CVCL_1274
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number37